ArticleHealth science reports2026
Prognostic Value of the C-Reactive Protein × Platelet-to-Lymphocyte Ratio for 28-Day Mortality in Patients With Sepsis: A Retrospective Cohort Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Inflammatory and hematologic biomarkers are commonly used for early risk assessment in sepsis. The C-reactive protein × platelet-to-lymphocyte ratio (CPL) integrates systemic inflammation, platelet-related thromboinflammation, and lymphocyte-associated immune suppression. This study aimed to evaluate the association between log-transformed CPL (lnCPL) and 28-day mortality in patients with sepsis and to assess its potential value as an adjunctive risk-stratification marker. Methods: This retrospective cohort study included 630 adult patients with sepsis admitted to the intensive care unit of a tertiary hospital between January 2022 and March 2025. CPL was calculated as CRP × platelet-to-lymphocyte ratio and then log-transformed. The primary outcome was 28-day all-cause mortality. Patients were stratified according to lnCPL quartiles, and lnCPL was additionally analyzed as a continuous variable. Multivariable logistic regression, restricted cubic spline analysis, receiver operating characteristic curve analysis, bootstrap internal validation, and admission-year sensitivity analysis were performed. Results: Among 630 patients, 115 died within 28 days, corresponding to a mortality rate of 18.3%. Mortality increased progressively across lnCPL quartiles, from 8.9% in Q1 to 31.6% in Q4. When modeled as a continuous variable, lnCPL was associated with increased 28-day mortality after adjustment for age, sex, SOFA score, GCS score, mechanical ventilation, CRRT, and AKI (OR = 1.716, 95% CI: 1.402-2.101, Conclusion: Higher lnCPL was associated with increased 28-day mortality in patients with sepsis and provided modest incremental discrimination beyond conventional clinical variables. However, because lnCPL overlaps with its inflammatory and hematologic components, it should be interpreted as an adjunctive risk-stratification marker rather than a standalone independent prognostic tool. Prospective multicenter validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.